Zeaxanthin

Zeaxanthin is a xanthophyll carotenoid that functions alongside lutein and meso-zeaxanthin as one of the three pigments comprising the macula lutea — the yellow spot in the central retina responsible for high-acuity daytime vision. Chemically zeaxanthin is (3R,3'R)-beta,beta-carotene-3,3'-diol, differing from lutein by the position of a single double bond in one of its two ionone rings. Lutein contains one beta-ionone ring and one epsilon-ionone ring, whereas zeaxanthin contains two symmetric beta-ionone rings with extended conjugation through both cyclic ends. This structural difference seems minor on paper but produces dramatically different behavior inside the human retina, and the co-supplementation of lutein with zeaxanthin at a roughly 5:1 ratio in AREDS2 reflects that the two molecules are complementary rather than redundant despite their near-identical chemistry.

The macular pigment exists as a spatial gradient across the central retina. In the outermost parafovea lutein dominates at roughly 2:1 over zeaxanthin. Moving inward toward the central fovea the ratio inverts — zeaxanthin becomes the dominant pigment at the foveal center, where cone density peaks and photopic acuity is maximal. At the centralmost point of the fovea, meso-zeaxanthin (the 3R,3'S stereoisomer) becomes the majority pigment. Meso-zeaxanthin does not meaningfully exist in the human diet; it is formed in situ from dietary lutein by an RPE65-like isomerase reaction in retinal pigment epithelium, which converts the 3'-hydroxyl-bearing epsilon-ring of lutein into the 3'S-configured beta-ionone ring of meso-zeaxanthin. The human retina thus concentrates dietary zeaxanthin and converts dietary lutein into meso-zeaxanthin to build a graded pigment system that maximizes blue-light filtration and singlet oxygen quenching precisely where photochemical retinal stress is highest.

Dietary sources of zeaxanthin are surprisingly narrow. Most green vegetables that provide lutein provide very little zeaxanthin — spinach, kale, and collards contain 10-20 mg of lutein per 100 g with less than 0.5 mg of zeaxanthin. The richest commonly consumed food sources of zeaxanthin are orange bell peppers (roughly 1.5-3 mg per pepper), corn (0.3-0.5 mg per cup), egg yolks (particularly from pastured hens, 0.1-0.3 mg per yolk with bioavailability enhanced by the phospholipid matrix), persimmons, and saffron. The singular non-commonplace dietary source that provides gram-per-day levels of zeaxanthin is goji berry (wolfberry, Lycium barbarum), which contains zeaxanthin dipalmitate as its dominant carotenoid at concentrations of 162-252 mg per 100 g dry weight according to Cheng 2005. Typical Western diets provide only 0.3-1 mg of zeaxanthin per day, well below the 2 mg dose validated in AREDS2, which is why supplementation is the practical route for most people pursuing evidence-based macular protection.

Commercial zeaxanthin for supplementation derives primarily from enhanced marigold (Tagetes erecta) flower extracts selectively bred or processed to shift the lutein:zeaxanthin ratio in favor of zeaxanthin, and secondarily from microbial fermentation using engineered strains. OPTISHARP (DSM) uses marigold-sourced zeaxanthin standardized to a consistent lutein:zeaxanthin ratio and is the ingredient used in most AREDS2-compliant eye health formulations. Lutemax 2020 is a proprietary blend that combines lutein, RR-zeaxanthin, and meso-zeaxanthin in a single ingredient — notable because meso-zeaxanthin is otherwise not commercially available as a standalone supplement. EZEyes is another branded marigold zeaxanthin ingredient used in premium formulations. Pricing for zeaxanthin is higher per milligram than for lutein because zeaxanthin is the minority carotenoid in marigold flowers and requires additional processing or strain selection to concentrate.

The evidence base for zeaxanthin supplementation rests primarily on the AREDS2 trial (Chew 2013 JAMA PMID 23644932), which randomized 4,203 participants with intermediate or advanced AMD in one eye to receive a modified AREDS formulation with lutein 10 mg plus zeaxanthin 2 mg replacing the original 15 mg beta-carotene. The primary endpoint — progression to advanced AMD — showed a 26% risk reduction in participants with the lowest dietary intakes of lutein plus zeaxanthin at baseline. Importantly, AREDS2 was not designed to isolate the effect of zeaxanthin alone from lutein; the two are always given together in the validated formulation because they are complementary rather than substitutable. Dietary epidemiology consistently finds zeaxanthin intake associated with lower AMD risk, and serum zeaxanthin concentrations correlate positively with macular pigment optical density (MPOD) measurements in a dose-dependent fashion. The Zeaxanthin and Visual Function Study (Richer 2011) specifically tested 8 mg daily zeaxanthin in early atrophic AMD patients for 12 months and found improvements in shape discrimination, glare recovery, and contrast sensitivity.

Beyond macular disease, zeaxanthin research has expanded into cataract prevention (Nurses' Health Study and Health Professionals Follow-up Study both showing inverse associations between zeaxanthin intake and cataract extraction rates), diabetic retinopathy (animal work and small human trials), visual performance in healthy young adults (including work by Stringham and Hammond showing zeaxanthin and lutein supplementation improving contrast sensitivity, photostress recovery, and disability glare tolerance), and cognitive function (Johnson 2014, Vishwanathan 2014 showing zeaxanthin concentrations in brain tissue correlate with cognitive performance in older adults). The visual performance work is directly relevant to young healthy consumers — Stringham's B.L.U.E. trial (2017) demonstrated that 12 mg daily lutein plus 2 mg zeaxanthin for 6 months improved sleep quality, reduced eyestrain and headache, and reduced visual fatigue in young adults with high screen exposure.

Pharmacokinetically zeaxanthin follows the same lipophilic absorption pathway as other carotenoids. It requires dietary fat for absorption, is packaged into chylomicrons in enterocytes, is delivered to the liver via chylomicron remnants, and then distributed to peripheral tissues via HDL particles. The scavenger receptor B1 (SR-B1) and the steroidogenic acute regulatory-related lipid transfer protein 3 (StARD3) mediate selective uptake into retinal pigment epithelium and neural retina. Blood zeaxanthin concentrations rise over 2-4 weeks of supplementation and plateau at about 8-12 weeks; macular pigment optical density rises more slowly, typically requiring 4-6 months to reach a new steady state and up to 12 months to fully accumulate. Half-life is long — retinal zeaxanthin turns over on the order of weeks rather than hours — so daily dosing is convenient but less critical than for shorter-half-life molecules.

Safety is well-established. Zeaxanthin does not share the beta-carotene problem seen in the CARET and ATBC trials, where high-dose beta-carotene supplementation increased lung cancer risk in heavy smokers. Xanthophylls (lutein and zeaxanthin are both xanthophylls) lack the pro-oxidant behavior that beta-carotene shows in smoker lung tissue under high oxygen tension. AREDS2 specifically tested the lutein-zeaxanthin substitution in a population that included former smokers and found no safety signal. The only commonly reported effect of high-dose zeaxanthin intake is carotenodermia — a harmless yellow-orange pigmentation of the skin, particularly palms and soles — which resolves when intake decreases. FDA GRAS status is established for zeaxanthin at up to 2 mg per day from food sources and higher levels are considered generally safe based on the AREDS2 data.

For bodyhackguide.co, zeaxanthin occupies a specific place in the eye-health and visual-performance arc. It is not a standalone supplement in practice — always paired with lutein at the AREDS2-validated ratio — and exists on the same shelf as astaxanthin (a more systemic antioxidant carotenoid without macular concentration), vitamin-e and vitamin-c (the other AREDS2 antioxidants), zinc and copper (the AREDS2 minerals), omega-3 (DHA is structurally enriched in retinal membranes), and bilberry (anthocyanin-based macular support with overlapping but distinct mechanism). Zeaxanthin without lutein makes no sense as a supplementation strategy; lutein without zeaxanthin is less-than-optimal because meso-zeaxanthin formation depends on lutein substrate but central foveal pigment deposition benefits from dietary zeaxanthin directly. The canonical recommendation for anyone with AMD risk factors, high screen time, glare sensitivity, or progressive visual aging is the AREDS2 formulation or an equivalent lutein 10 mg plus zeaxanthin 2 mg combination taken daily with a fat-containing meal for 6-12 months before expecting a detectable change in MPOD or visual performance.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Zeaxanthin Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness